Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA
Sotorasib plus panitumumab did not demonstrate an economic advantage compared to standard care in the treatment of refractory CRC with mutated KRAS<sup>G12C</sup> in the U.S.A.
Authors
- Zhiqiang Tong
- Yao Yao (ORCID: https://orcid.org/0000-0003-1116-9461)
- Ruihong Yao
- Tong Liu (ORCID: https://orcid.org/0000-0001-9234-1328)
- Mei Dong (ORCID: https://orcid.org/0000-0003-1735-5361)
- Teng Xue
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1080/14737167.2025.2521444
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Heilongjiang Province